LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

This study is a rolling arm study of pembrolizumab in combination with investigational agents in pediatric participants with relapsed or refractory classical Hodgkin lymphoma (cHL) solid tumors with microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) or tumor mutational burden-high (TMB-H). This study will have 2 parts: a safety lead-in to demonstrate a tolerable safety profile and confirm a preliminary recommended phase 2 dose (RP2D) (Part 1) followed by an efficacy evaluation (Part 2). Participants will be assigned to a treatment arm (either Part 1 or Part 2) that is open for enrollment.
There will be no hypothesis testing in this study.

开始日期2024-12-13

申办/合作机构

Merck Sharp & Dohme LLC

NCT04305054 / Recruiting临床1/2期

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B

Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn:
* About the safety and how well people tolerate pembrolizumab given with other treatments
* How many people have melanoma that responds (gets smaller or goes away) to treatment
Arm 1: Pembrolizumab + Vibostolimab was added in the base protocol on 13-Nov-2019, and enrollment into this arm has been completed. Arm 2: Pembrolizumab was added in the base protocol on 13-Nov-2019, and enrollment stopped prematurely on 15-Aug-2022. Arm 3: Coformulation Pembrolizumab/Quavonlimab was added in Amendment 01 on 20-Oct-2020, and enrollment stopped prematurely on 15-Aug-2022. Arm 4: Coformulation Pembrolizumab/Quavonlimab + Lenvatinib was added in Amendment 01 on 20-Oct-2020, and enrollment is ongoing. Arm 5: Coformulation Favezelimab/Pembrolizumab was added in Amendment 03 on 01-DEC-2022 and has paused enrollment, Arm 6: Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA) was added in Amendment 03 on 01-DEC-2022 and has paused enrollment, and Arm 7: Coformulation Favezelimab/Pembrolizumab + Vibostolimab was added in Amendment 03 on 01-DEC-2022 and enrollment was stopped prematurely on 22-SEP-2023.

开始日期2020-07-01

申办/合作机构

Merck Sharp & Dohme Corp.

NCT04305041 / Active, not recruiting临床1/2期

A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.
As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.

开始日期2020-06-26

申办/合作机构

Merck Sharp & Dohme Corp.

100 项与 Vibostolimab 相关的临床结果

登录后查看更多信息

100 项与 Vibostolimab 相关的转化医学

登录后查看更多信息

100 项与 Vibostolimab 相关的专利（医药）

登录后查看更多信息

项与 Vibostolimab 相关的文献（医药）

2024-08-26·Future Oncology

The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies

Article

作者: Ahn, Myung-Ju ; Peters, Solange ; Shouse, Geoffrey ; Lugowska, Iwona ; Garassino, Marina C. ; Zhao, Bin ; Sands, Jacob ; Niu, Jiaxin ; Keenan, Tanya ; Perets, Ruth ; Healy, Jane ; Shapira-Frommer, Ronnie

Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has shown promising antitumor activity, warranting further exploration of vibostolimab as a potential therapeutic option. The KEYVIBE program consists of nine trials that will evaluate the safety and efficacy of vibostolimab monotherapy and vibostolimab-based combination therapy in advanced solid tumors and hematological malignancies. These studies will also evaluate coformulated immunotherapy addressing issues that occur with the sequential administration of immunotherapy. The KEYVIBE program will provide further insight into the clinical utility of vibostolimab-based therapy across multiple indications and various stages of disease.

2023-08-01·Cancer letters

TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer

Article

作者: Xing, Nianzeng ; Wang, Jing ; Li, Jianxing ; Ma, Jianlin ; Wang, Fangming ; Liu, Fei ; Yang, Feiya ; Xu, Tianli ; Liang, Jing ; Liu, Shuai ; Liu, Donghua

Castration-resistant prostate cancer (CRPC) patients have a 14-month median survival, emphasizing the need for alternative treatments. Previously, we demonstrated that expanded high-dose natural killer (NK) cells derived from human peripheral blood exhibit therapeutic efficacy against CRPC. However, which immune checkpoint blockade promotes NK cell antitumor immunity against CRPC remains unknown. Here, we explored immune checkpoint molecule expression in NK and CRPC cells during their interactions, and identified that the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) monoclonal antibody (mAb), vibostolimab, significantly enhanced NK cell cytotoxicity against CRPC cells and cytokine production in vitro, demonstrated by upregulation of degranulation marker CD107a and Fas-ligand (Fas-L) and increased interferon-gamma (IFN-γ) and tumor necrosis factor-alpha secretion. TIGIT blockade increased Fas-L expression and IFN-γ production via the NF-κB signaling pathway and restored degranulation via the mitogen-activated protein kinase ERK (extracellular signal-regulated kinase) kinase/ERK pathway in activated NK cells. Vibostolimab significantly enhanced NK cell antitumor effects against CRPC in two xenograft mouse models. Vibostolimab also increased T cell chemotaxis induced by activated NK cells in vitro and in vivo. Overall, blocking TIGIT/CD155 signaling enhances the antitumor effect of expanded NK cells against CRPC; this finding supports the translational application of TIGIT mAb and NK cell combination strategies from bench to bedside for CRPC treatment.

2023-04-01·ESMO open

Anti-TIGIT therapies for solid tumors: a systematic review

Review

作者: Barlesi, F ; Rousseau, A ; Parisi, C

Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif domains] antibodies. TIGIT is an immune checkpoint inhibiting lymphocyte T cells by several mechanisms. In vitro models showed its inhibition could restore antitumor response. Furthermore, its association with anti-PD-(L)1 therapies could synergistically improve survival. We carried out a review of the clinical trial about TIGIT referenced in the PubMed database, finding three published clinical trials on anti-TIGIT therapies. Vibostolimab was evaluated in a phase I alone or in combination with pembrolizumab. The combination had an objective response rate of 26% in patients with a non-small-cell lung cancer (NSCLC) naïve of anti-programmed cell death protein 1 (anti-PD-1). Etigilimab was tested in a phase I alone or in combination with nivolumab, but the study was stopped due to business reasons. In the phase II CITYSCAPE trial, tiragolumab demonstrated higher objective response rate and progression-free survival in combination with atezolizumab than atezolizumab alone in advanced PD-L1-high NSCLC. The ClinicalTrials.gov database references 70 trials of anti-TIGIT in patients with cancer, 47 of them with ongoing recruitment. Only seven were phase III, including five about patients with NSCLC, mostly with combination therapy. Data from phase I-II trials highlighted that targeting TIGIT represents a safe therapeutic approach, with an acceptable toxicity profile maintained when adding anti-PD-(L)1 antibodies. Frequent adverse events were pruritus, rash, and fatigue. Grade 3-4 adverse events were reported in nearly one in three patients. Anti-TIGIT antibodies are under development as a novel immunotherapy approach. A promising research area includes the combination with anti-PD-1 therapies in advanced NSCLCs.

102

项与 Vibostolimab 相关的新闻（医药）

2024-12-18

·生物制药进展杂评

TIGIT：从默沙东、罗氏的接连失败回看当年的二选一赌局

TIGIT这个靶点从跟踪开始，一直就是失败、希望、再失败，循环到最后罗氏和默沙东都最终止损；期间写过一直在关注也写过几篇文章罗氏TIGIT+PD-L1组合治疗非小细胞肺癌，结果很不错！我们是如何错失TIGIT靶点布局良机的——立项格局再反思 TIGIT临床再次失败 TIGIT联合PD1单抗在II期治疗NSCLC 中提高PFS，看到了翻盘的希望默沙东终止 vibostolimab（ TIGIT ）和 favezelimab（ LAG-3 ）的临床开发项目在2019年一篇文章中当时还在思考TIGIT到底怎么个发挥作用，成药性如何，现在已经在临床妥妥的验证了，会看一下，还是很有趣肿瘤免疫治疗：二选一赌局中的TIGIT靶点杂谈在2009年TIGIT首次被发现，TIGIT属于PVR家族（poliovirus recptor）。有意思的是在T细胞被激活后TIGIT的表达会内源性抑制T细胞活性，此外还大量表达在Trg细胞表面并通过诱导IL-10和Fgl2表达增强Treg对免疫系统的负调控作用。于是在肿瘤免疫浪潮下，TIGIT很快被推上了临床，成为和PD-(L)1联合使用的热门潜在靶点，尽管人们对这个靶点的认识还不够深入。在研究中让人们很疑惑的一点是：尽管同时抑制PD-1和TIGIT 可以重新激活CD8+TIL的活性，但是如果把表达TIGIT的基因敲除掉并同时抑制PD-1则不会增强CD8+TIL的抗肿瘤活性[1]。这至少说明，仅仅抑制CD8+TIL表面的TIGIT并不会比单独使用PD-1抗体取得更好的抗肿瘤效果，在肿瘤微环境中以Treg为代表的其他细胞高表达TIGIT仍然会对CD8+TIL起到旁路负调控作用。从这个机理上来说，抗体的开发一定是需要减弱或者消除Fc区域的ADCC和CDC功能，才能保证T细胞最大发挥作用，但是双刃剑的另一面就是对Treg的作用就相对减弱。此外TIGIT的受体除了CD112之外还有CD155，而CD122-PVRIG信号通路仍然会对CD8+TIL细胞具有抑制作用。因此是否可以推测在敲除掉CD8+TIL细胞中TIGIT 基因之后，除了TAM中其他细胞因表达TIGIT产生IL-10等细胞因子负调控T细胞的抗肿瘤作用之外，CD122-PVRIG信号通路的代偿增加也会进一步抵消敲除TIGIT抑制信号之后的作用。最终会导致单独阻断TIGIT信号通路，对T细胞抗肿瘤效果无显著作用。因此这么看看来单独使用TIGIT+PD-1抗体的联用，似乎会有一些缺憾，甚至难以达到预期的增强抗肿瘤的作用。当然从开发药物的角度，现在开始进行临床研究是无可厚非。因为在这个竞争激烈的时代你不会指望等所有基础研究都透彻之后再开始动手；反过来说，药物的开发始终是以临床效果为导向，只有好的临床效果才能验证一切体外甚至动物体内的实验数据的准确性。理论总是纸上谈兵，实践才是检验真理的唯一标准。没有一点风险的药物开发是不存在的，所以还是致敬这些勇于尝试的先驱者。 [1] Kurtulus, S. et al. TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Invest. 125, 4053–4062 (2015). 这篇文章也挺有趣，今年撤稿了，里面三个图的数据涉嫌造假

免疫疗法临床终止临床结果临床失败

2024-12-18

·摩熵医药

默沙东终止开发TIGIT和LAG-3抗体项目，明星靶点全面失败！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 12月16日，默沙东(MRK.US)发布公告，宣布终止开发抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab。这两个项目旨在探索两种免疫肿瘤药物的组合，以期在多种癌症类型中提高患者的生存率。两个项目的终止也标志着公司在这些特定癌症治疗研究领域努力的结束。 01 TIGIT单抗研发受挫全球药企面临挑战近年来，TIGIT与LAG-3作为继PD-1后的热门免疫靶点，备受全球药企瞩目。跨国药企如默沙东、罗氏，以及国内药企信达、君实等均在TIGIT抗体上投入巨资，但遗憾的是，研发成果多不如意。在今年7月份，罗氏宣布SKYSCRAPER-06研究（全球随机对照II/III期）未达到主要终点PFS、OS。该研究旨在评估tiragolumab （TIGIT单抗）+Tecentriq (atezolizumab，PD-L1单抗)+化疗 vs. pembrolizumab（K药）+化疗一线治疗局部晚期不可切除或转移性非鳞状非小细胞肺癌（共入组了542例患者）。未来双抗产品也许还值得期待一下：目前全球共14个TIGIT双抗产品进入临床阶段，其中和PD-1/L1组合的有7个。联合给药不行，双抗未必不行，PD-1/VEGF就是和好的例子。鉴于默沙东在PD-1/VEGF上面的表现，未来说不定也会有一款PD-1/TIGIT横空出世。默沙东的K药联合TIGIT单抗在非小细胞肺癌的临床试验中遭遇挫折，效果甚至不及化疗组，导致该研究被终止。此后，默沙东又根据临床数据终止了两项非小细胞肺癌的三期试验及Vibostolimab的开发计划。同样，罗氏也宣布其PD-L1联合TIGIT单抗的三期临床未达到主要终点，使得TIGIT单抗的研发之路更加坎坷。这些项目的终止并非偶然。几个月来，TIGIT组合的安全性担忧以及免疫肿瘤（IO/IO）组合历史上的失败记录使得药企在研发过程中面临巨大挑战。在预先计划的分析中，KeyVibe-003和KeyVibe-007研究都未达到OS这一主要终点的预先设定标准，且固定剂量组合治疗组发生的免疫相关不良事件较多。 02 曾经的PD-(L)1联用明星靶点在全球范围内，罗氏与默沙东长期领跑TIGIT单抗的研发赛道，已历经八九年的持续投入与激烈竞争。鉴于TIGIT单药疗效有限，当前药企普遍采取的策略是将PD-(L)1与TIGIT联用。这一趋势源自罗氏在2020年ASCO上公布的积极数据，其PD-L1与TIGIT单抗联用治疗非小细胞肺癌的二期研究结果显示，相比PD-L1单药组，联用组实现了ORR的显著改善，尤其在PD-L1高表达患者中效果更佳。此后，TIGIT迅速成为热门靶点，吸引了阿斯利康、百时美施贵宝、GSK等多家跨国药企的重金投入。国内药企也紧随其后，百济神州与君实生物分别完成了对外授权，其中百济神州与诺华的合作更是创造了高达数亿美元的交易价值。默沙东的K药与TIGIT单抗的组合被视为该领域的标杆，其主要开发的适应症为非小细胞肺癌。作为拥有K药这一“药王”的巨头，默沙东一直在探索K药与其他药物的联用方案，以拓展其治疗潜力。同样，国内药企百济神州也对TIGIT靶点寄予厚望。然而，好景不长。近年来，TIGIT单抗的研发遭遇挫折。2023年，诺华退回了百济神州TIGIT抗体欧司珀利单抗的部分海外权益，而君实生物也宣布其合作伙伴Coherus终止了关于TIGIT单抗的合作。这些变故表明，尽管TIGIT曾被视为PD-(L)1联用的新星，但目前其研发前景仍面临诸多挑战。结语综上所述，TIGIT单抗的研发之路坎坷不平，全球药企在探索该领域的过程中面临巨大挑战。随着默沙东的退出，现在只剩罗氏还有TIGIT管线在临床三期。今年1月，罗氏TIGIT抗体联合疗法在治疗食管鳞状细胞癌的临床3期试验中取得积极结果，试验达到双主要终点，PD-L1+TIGIT+化疗方案可显著改善患者的无进展生存期与总生存期。同时，肝癌的临床研究也在进行中，罗氏的成功与否，将直接影响TIGIT的成药前景及其他药企的开发策略。 END 近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

ASCO会议临床3期临床结果临床2期免疫疗法

2024-12-18

·生物制品圈

默沙东：终止两个肿瘤项目

12月16日，默沙东(MRK.US)发布公告，宣布终止开发抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab。这两个项目旨在探索两种免疫肿瘤药物的组合，以期在多种癌症类型中提高患者的生存率。两个项目的终止也标志着公司在这些特定癌症治疗研究领域努力的结束。终止这些项目的决定是在几个月来出现安全性担忧（特别是TIGIT组合）以及免疫肿瘤（IO/IO）组合历史上的失败记录之后做出的。在预先计划的分析中，KeyVibe-003研究和KeyVibe-007研究都达到了OS这一主要终点的预先设定的无效标准。默沙东表示，固定剂量组合治疗组发生的免疫相关不良事件比帕博利珠单抗单药治疗组多。基于现有的KeyVibe系列研究的全部数据，默沙东决定终止III期KeyVibe-006研究和Vibostolimab的其他临床研究。此外，基于现有的所有临床数据，默沙东也决定终止Favezelimab的临床开发项目，并将终止III期KEYFORM-008研究。已入组患者可以继续接受治疗直至研究完成。KEYFORM-008研究是KEYFORM临床开发计划中唯一一项尚未获得结果的III期研究。默沙东强调，这一终止决定与MK-4280A的安全性无关。此前，因为免疫副作用，默沙东还停止了K药+TIGIT联用辅助治疗黑色素瘤的三期临床。今年8月，默沙东再次终止了K药+TIGIT用于一线治疗小细胞肺癌的三期临床。数据显示，临床的总生存期（OS）的主要终点符合预先设定的无效标准。此外，与对照组相比，联用方案的不良事件发生率更高。 11月26日，罗氏宣布PD-L1（Atezolizumab）联合TIGIT单抗tiragolumab，用于非小细胞肺癌患者的三期临床没有达到总生存率的主要终点。7月4日，罗氏宣布非鳞状非小细胞肺癌的II/III期临床研究未达到主要终点。纵观全球，罗氏和默沙东是最积极开发TIGIT单抗的，已经坚持开发了八九年，双方竞速多年。但目前来看，只有罗氏还有TIGIT管线在临床三期。今年1月，罗氏TIGIT抗体联合疗法用于一线治疗食管鳞状细胞癌的一项临床3期试验获得积极结果。试验达到双主要终点，PD-L1+TIGIT+化疗方案可显著改善患者的无进展生存期与总生存期。肝癌的临床也在推进中。关于 Vibostolimab Vibostolimab （MK-7684）是由默沙东发现和开发的一种研究性人源化抗 TIGIT 抗体。Vibostolimab 通过阻断 TIGIT 受体与其配体（CD112 和 CD155）结合来恢复抗肿瘤活性，从而激活有助于破坏肿瘤细胞的 T 淋巴细胞。关于 Favezelimab Favezelimab （MK-4280）是一种研究性抗淋巴细胞活化基因 3 （LAG-3）抗体。LAG-3 是一种在各种免疫细胞上表达的细胞表面免疫调节受体，可下调 T 细胞增殖和活化。Favezelimab 旨在通过阻止 LAG-3 与其主要配体、主要组织相容性复合体（MHC） II 类分子结合来恢复 T 细胞效应器功能。参考资料：公司官网识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

临床3期临床成功临床2期临床结果临床失败

100 项与 Vibostolimab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11795	-	-	DB16420

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌	临床3期	美国	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	中国	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	智利	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	危地马拉	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	俄罗斯	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	韩国	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	土耳其	Merck Sharp & Dohme Corp.	2021-04-07
非小细胞肺癌	临床3期	乌克兰	Merck Sharp & Dohme Corp.	2021-04-07
血液肿瘤	临床2期	美国	Merck Sharp & Dohme LLC	2024-12-13
血液肿瘤	临床2期	韩国	Merck Sharp & Dohme LLC	2024-12-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04303169 (KEYMAKER-U02, ESMO2024) 人工标引	临床1/2期	黑色素瘤	117	Pembrolizumab + Vibostolimab	淵膚簾範簾憲觸鹹鏇築(觸製顧廠膚積憲窪膚積) = 選製醖獵夢鬱構夢觸鑰鬱顧簾範淵廠積餘鬱遞 (夢築鹽憲壓壓鬱網鹹窪 ) 更多	积极	2024-09-14
				Pembrolizumab + Gebasaxturev	淵膚簾範簾憲觸鹹鏇築(觸製顧廠膚積憲窪膚積) = 窪製餘鹹鏇顧衊憲鬱鹹鬱顧簾範淵廠積餘鬱遞 (夢築鹽憲壓壓鬱網鹹窪 ) 更多
ESMO2024	N/A	晚期头颈部鳞状细胞癌	-	Vibostolimab coformulated with pembrolizumab (vibo/pembro)	憲鑰餘構製遞壓壓蓋鑰(膚簾醖憲製鬱繭艱積遞) = 繭積醖鏇蓋餘壓蓋鹽繭窪願願齋窪遞襯窪鑰夢 (築鏇齋夢繭願範繭夢鏇 ) 更多	-	2024-09-14
TIGIT (NEWS) 人工标引	临床2期	转移性非小细胞肺癌	-	vibostolimab+Keytruda	憲製膚鹽鬱構繭艱齋壓(製積構鏇獵窪糧夢齋糧) = 蓋鏇築襯願鏇願網構遞艱窪願範餘繭築淵鏇製 (醖積遞壓願膚積網鹽膚 ) 更多	不佳	2023-12-07
				docetaxel	憲製膚鹽鬱構繭艱齋壓(製積構鏇獵窪糧夢齋糧) = 鬱鹽繭願衊廠糧餘鑰壓艱窪願範餘繭築淵鏇製 (醖積遞壓願膚積網鹽膚 ) 更多
NCT04303169 (KEYMAKER-U02 substudy 02C \| 3475-02C \| KEYMAKER-U02 \| MK-3475-02C, AACR2023) 人工标引	临床1/2期	黑色素瘤新辅助	66	pembrolizumab+vibostolimab (arm 1)	鏇膚夢願範襯淵鬱衊糧(廠醖蓋築鏇衊製淵觸蓋) = 選夢願繭製壓艱顧鑰範齋鑰繭鬱繭襯襯壓衊簾 (積鏇範製夢顧選願鬱齋 ) 更多	积极	2023-04-14
				pembrolizumab+gebasaxturev (arm 2)	鏇膚夢願範襯淵鬱衊糧(廠醖蓋築鏇衊製淵觸蓋) = 襯衊壓鏇蓋範觸醖積築齋鑰繭鬱繭襯襯壓衊簾 (積鏇範製夢顧選願鬱齋 ) 更多